Ace the Case: A 62-Year-Old Man Presents With Increasing Fatigue, Weight Loss, and Night Sweats for the Past 8 Months


You passed! Review the answers below.

Please try again. The questions you answered incorrectly are highlighted in red below.

Question 1
Which of the following agents is an oral inhibitor of BCL-2?
Please complete this question.
Please try again.

Correct Answer: B.

Rationale: Venetoclax is a first-in-class oral inhibitor of BCL-2, an anti-apoptotic protein implicated in the pathology of CLL.38 This agent was approved by the FDA in 2016 for the treatment of patients with 17p deletions who have received at least 1 previous course of therapy.39